---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-024514"
form_type: "8-K"
ticker: "AIMD"
cik: "0001014763"
company_name: "Ainos, Inc."
filed_at: "2024-06-20T23:59:59+00:00"
generated_at: "2026-06-01T03:11:21.671049+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ainos reports 75-case clinical trial progress for Ainos Flora; next-gen device with NVIDIA CUDA targeting Q3/Q4

## Summary
- Clinical trials for AI Nose-powered Ainos Flora achieved 75 meaningful case results, validating AI algorithm model.
- Next-gen Ainos Flora will leverage NVIDIA CUDA for accelerated deep learning; design completion expected Q3, clinical trials Q4.
- Second-generation device targets at-home testing for viral infections, expanding beyond bacterial/fungal/STI detection.
- Board approved amended bylaws reducing stockholder meeting quorum to one-third and adding advance notice procedures.
- STI testing market projected US$256B by 2028; POCT accounts for 31%, presenting opportunity for telehealth-friendly rapid testing.

## SEC filing metadata
- accession: 0001493152-24-024514
- form_type: 8-K
- ticker: AIMD
- cik: 0001014763
- company_name: Ainos, Inc.
- filed_at: 2024-06-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1014763/000149315224024514/0001493152-24-024514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1014763/000149315224024514/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-024514
- JSON: https://secwatch.observer/filing/0001493152-24-024514.json
- Plain text: https://secwatch.observer/filing/0001493152-24-024514.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.